EIM
NBSE

Essex Investment Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Essex Investment Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-187
Closed -$190K – 343
2015
Q1 		$190K Buy
+187
New +$617K 0.03% 300

Other funds holding NBSE

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $152M AUM 20.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Essex Investment Management's NBSE Position: Q2 2015 in Review

Essex Investment Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2015, closing a stake of 187 shares — an estimated $190K sold.

Essex Investment Management first reported a position in NBSE in Q1 2015 and held it in 1 quarter. The position peaked at $190K in Q1 2015. 66 funds tracked by Wall St. Rank hold NBSE as of Q2 2015.

  • Essex Investment Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Essex Investment Management sold 187 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $190K.
  • Essex Investment Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • Essex Investment Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $190K in Q1 2015.
  • 66 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Essex Investment Management's 13F filing for Q2 2015, filed 28 Jul 2015.